Medincell (XPAR:MEDCL) EBITDA Margin % : -70.08% (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medincell EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medincell's EBITDA for the six months ended in Sep. 2023 was €-4.90 Mil. Medincell's Revenue for the six months ended in Sep. 2023 was €6.99 Mil. Therefore, Medincell's EBITDA margin for the quarter that ended in Sep. 2023 was -70.08%.

Medincell EBITDA Margin % Historical Data

The historical data trend for Medincell's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell EBITDA Margin % Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBITDA Margin %

Get a 7-Day Free Trial

-1,164.80

-633.70

-187.88

-524.35

-265.62

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial										-637.03	-452.25	-183.82	-391.47	-70.08

Competitive Comparison of Medincell's EBITDA Margin %

For the Biotechnology subindustry, Medincell's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Medincell's EBITDA Margin % falls into.

Medincell EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Medincell's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-26.413	/	9.944
	=	-265.62 %

Medincell's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-4.895	/	6.985
	=	-70.08 %

Medincell (XPAR:MEDCL) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Medincell EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Medincell's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines